)
Edge14 Nov 2025
Ball: The King of Cans
From a 19th-century glass-jar legacy to a global plant network, Ball is now a pure-play aluminum can partner to the world's biggest beverage brands.
SCYNEXIS (SCYX) investor relations material
SCYNEXIS Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary5 Nov, 2025
Executive summary
Resolved a dispute with GSK, resulting in a $24.8M one-time payment and termination of the Phase 3 MARIO study; future milestones and royalties for BREXAFEMME remain intact, with GSK planning a relaunch in 2026.
Focused on developing novel antifungal agents, with ibrexafungerp (BREXAFEMME) approved for VVC and rVVC, and SCY-247 advancing in clinical trials with positive Phase 1 data.
GSK's relaunch of BREXAFEMMEⓇ could yield up to $146M in annual net sales milestones and royalties.
Ended Q3 2025 with $37.9M in cash, cash equivalents, and investments; post-GSK payment, cash runway extends beyond two years.
Financial highlights
License agreement revenue was $0.3M for Q3 2025, down 49% year-over-year; nine-month revenue was $2.0M, down 29%.
Net loss for Q3 2025 was $8.6M ($0.17 per share), compared to $2.8M ($0.06 per share) in Q3 2024; nine-month net loss was $20.9M, up from $16.9M year-over-year.
Research and development expenses decreased 33% to $5.5M in Q3 2025; selling, general, and administrative expenses rose 13% to $3.3M.
Cash, cash equivalents, and investments totaled $37.9M as of September 30, 2025, down from $75.1M at year-end 2024.
Outlook and guidance
Capital resources are expected to fund operations for at least 12 months, with cash runway exceeding two years post-GSK payment; additional funding will be needed for continued R&D and operations.
SCY-247 IV Phase 1 and proof-of-concept Phase 2 studies are planned for 2026, targeting invasive candidiasis and prevention of invasive fungal diseases.
Exploring non-dilutive funding to support SCY-247 development.
GSK's future strategy for ibrexafungerp
SCY-247 non-dilutive funding options
Assumptions for 2-year cash runway
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next SCYNEXIS earnings date
Q4 202512 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
SCYNEXIS Inc. is a biotechnology company focused on the research, development, and commercialization of innovative therapies for fungal infections. The company's lead product, based on a novel antifungal platform, is designed to address severe and drug-resistant fungal infections in both hospital and outpatient settings. SCYNEXIS develops treatments for conditions with significant unmet medical needs, with a particular emphasis on antifungal agents targeting life-threatening infections. The company is headquartered in Jersey City, USA, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage